USANA Restructuring Plan Highlights Both Promise and Peril

What happened

USANA is executing a restructuring plan that management promises will reset costs and improve margins, but the DeepValue report rates the stock a WAIT, citing unproven execution and still-declining direct-selling customers. The Seeking Alpha article touts the plan as making USANA a Strong Buy, noting temporary margin pressure from promotions at Rise Wellness and higher CAC at Hiya due to Meta algorithm changes. However, the DeepValue analysis emphasizes that Q3 2025 EBITDA margin collapsed to ~6.4%, Hiya remains loss-making, and direct-selling active customers are falling double-digits. The restructuring includes a $4.7M charge and targets cost savings, but the market needs to see at least 10% EBITDA margins and customer stabilization before the thesis improves. Until those metrics materialize, the deep-value price (book value ~$0.75x) reflects the uncertainty, not a clear upside.

Implication

In the near term, the restructuring plan introduces execution risk and potential for further margin compression, so investors should avoid adding positions until at least one clean quarter of EBITDA margins above 10% and flattish customer trends emerge. Over the longer term, if USANA successfully rightsizes costs and Hiya achieves breakeven, the stock could re-rate toward book value or higher, offering substantial upside from current levels. However, failure to stabilize the direct-selling base or continued losses at Hiya could lead to goodwill impairments and a bear-case valuation near $15 per share. The DeepValue report's base-case implied value is $24, requiring margin recovery to ~9-10%, which is not yet visible. Thus, the prudent approach is to monitor Q4 2025 and FY26 guidance for concrete signs of a turnaround before committing capital.

Thesis delta

This new article introduces a more optimistic view of the restructuring plan than the DeepValue report's cautious stance, but it does not provide new fundamental data that changes the core thesis. The thesis remains dependent on visible evidence of customer and margin stabilization, which has not yet materialized. Therefore, the WAIT rating is retained, with the restructuring plan as a potential catalyst that could increase conviction if executed successfully.